Van Hees, S., Bourgeois, S., Van Vlierberghe, H., Sersté, T., Francque, S., Michielsen, P., . . . Vanwolleghem, T. (2018). Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. Aliment Pharmacol Ther.
Citação norma ChicagoVan Hees, S., et al. "Stopping Nucleos(t)ide Analogue Treatment in Caucasian Hepatitis B Patients After HBeAg Seroconversion Is Associated With High Relapse Rates and Fatal Outcomes." Aliment Pharmacol Ther 2018.
MLA citiranjeVan Hees, S., et al. "Stopping Nucleos(t)ide Analogue Treatment in Caucasian Hepatitis B Patients After HBeAg Seroconversion Is Associated With High Relapse Rates and Fatal Outcomes." Aliment Pharmacol Ther 2018.